期刊文献+

小鼠破骨细胞骨髓诱导模型的建立及功能观察 被引量:3

Establishment of experimental model of osteoclast differentiation induced by bone marrow mononuclear phagocytes of mouse
下载PDF
导出
摘要 目的获得大量高质量小鼠破骨细胞,为体外研究破骨细胞骨吸收功能提供丰富的细胞来源。方法采用巨噬细胞集落刺激因子(macrophage colony stimulating factor,M-CSF)和破骨细胞分化因子(receptor activator of nuclear factor-κB ligand,RANKL)诱导小鼠骨髓单核细胞分化为破骨细胞,并通过抗酒石酸酸性磷酸酶(tartrate-resistant acid phos-phatase,TRAP)染色和骨吸收实验来鉴定破骨细胞及其噬骨能力。结果诱导3d后可见TRAP(+)多核细胞出现,诱导5d后骨片上可见蓝紫色的吸收陷窝。随着培养时间的延长,TRAP(+)多核细胞数目和吸收陷窝呈现时间依赖性增长趋势(P<0·05)。结论M-CSF和RANKL诱导小鼠骨髓单核细胞可产生大量的具有活跃噬骨能力的破骨细胞。 Objective To obtain plenty of pure osteoclasts for researching the function of osteoclasts in vitro. Methods Osteoclasts were induced by bone marrow mononuclear phagocytes of mouse using medium with macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor-kappaB ligand (RANKL). The tartrate resistant acid phosphatase (TRAP) staining and bone resorption experiment were used to identify the osteoclasts. Results The TRAP positive multinuclear ceils were induced from mouse bone marrow mononuclear phagocytes after 3 days of inoculation, and plenty of resorption pits formed on bone slices after 7 days of inoculation. The number of TRAP positive multinuclear ceils and bone resorption pits gradually increased during the period of induction. Conclusion The osteoclasts were successfully induced from bone marrow mononuclear phagocytes in the presence of M-CSF and RANKL.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2008年第6期521-524,共4页 Journal of Third Military Medical University
基金 国家重点基础研究发展规划项目(“973”项目)(2005CB522604) 国家自然科学杰出青年基金(30425023) 国家自然科学基金(30530410)~~
关键词 破骨细胞 TRAP染色 骨吸收 osteoclast tartrate resistant acid phosphatase bone resorption
  • 相关文献

参考文献6

  • 1刘波,于世凤,庞淑珍.新伐他汀体外对破骨细胞性骨吸收及大鼠骨代谢的影响[J].中国骨质疏松杂志,2005,11(3):351-355. 被引量:13
  • 2Takahashi N,Udagawa N,Tanaka S,et al.generating murine osteoclasts from bone marrow[J].Methods Mol Med,2003,80:129-144.
  • 3Asagiri M,Takayanagi H.the molecular understanding of osteoclast differentiation[J].Bone,2007,40(2):251-264.
  • 4Boyle W J,Simonet W S,Lacey D L.Osteoclast differentiation and activation[J].Nature,2003,423(6937):337-342.
  • 5Kartsogiannis V,Ng K W.Cell lines and primary cell cultures in the study of bone cell biology[J].Mol Cell Endocrinol,2004,228(1-2):79-102.
  • 6Kim H J,Zhao H,Kitaura H,et al.Gluocorticoids suppress bone formation via the osteoclast[J].J Clin Invest,2006,116(8):2152-2160.

二级参考文献11

  • 1史凤芹,于世凤.体外破骨细胞分离培养方法的建立[J].中华骨科杂志,1994,14(1):43-46. 被引量:28
  • 2史凤芹,于世凤,庞淑珍,朱晓滨.兔破骨细胞体外分离培养方法的改良[J].中华病理学杂志,1996,25(6):379-380. 被引量:9
  • 3Mundy G, Garrett R, Harris S,et al. Stimulation of bone formation in vitro and in rodents by statins. Science, 1999, 286 (5446):1946-1949.
  • 4Wang EA, Israel DI, Kelly S, et al. Bone morphogenetic protein-2causes commitment and differentiation in C3H10T1/2 and 3T3 cells.Growth Factors, 1993,9: 57-71.
  • 5Katagiri T, Yamaguchi A, Ikeda T, et al. The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun, 1990,172: 295-299.
  • 6Van der Horst G, Van Bezooijen RL, Deckers MM, et al.Differentiation of murine preosteoblastic KS483 cells depends on autocrine bone morphogenetic protein signaling during all phases of osteoblast formation. Bone, 2002,31: 661-669.
  • 7Mundy GR. Statins: potential new anabolic agents for treatment of osteoporosis. Int Bone Forum, 1999.22-27.
  • 8Chambers TJ, Magnus CJ. Calcitonin alters behavior of isolated osteoclasts. J Pathol, 1982,136: 27-39.
  • 9Fisher JE, Rogers M J, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway,prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA, 1999,96:133-138.
  • 10Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and Survival:inhibition by bisphosphonates and GGTI-298. J Bone Miner Res, 2000,15:1467-1476.

共引文献12

同被引文献37

  • 1李斌斌,于世凤,庞淑珍.两种破骨细胞培养方法的比较及其吸收骨质的动态观察[J].北京大学学报(医学版),2005,37(5):536-541. 被引量:14
  • 2戚楠,马清钧.长效重组蛋白药物的研究进展[J].中国生物工程杂志,2006,26(2):79-82. 被引量:22
  • 3McClung MR.Inhibition of RANKL as a treatment for osteoporosis:preclinical and early clinical studies.CurrOsteoporos Rep,2006,4(1):28-33.
  • 4Zauli G,Melloni E,Capitani S,et al.Role of full-lengthosteoprotegerin in tumor cell biology.Cell Mol Life Sci,2009,66(5):841-851.
  • 5Zierhut ML,Gastonguay MR,Martin SW,et al.Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausalwomen.J Pharmacokinet Pharmacodyn,2008,35(4):379-399.
  • 6Armstrong AP,Miller RE,Jones JC,et al.RANKL acts directlyon RANK-expressing prostate tumor cells and mediates migrationandexpression of tumor metastasis genes.Prostate,2008,68(1):92-104.
  • 7Zinonos I,Labrinidis A,Lee M,et al.Anticancer efficacy ofApo2L/TRAIL is retained in the presence of high and biologicallyactive concentrations of osteoprotegerin in vivo.J Bone MinerRes,2011,26(3):630-643.
  • 8Gemgross TU,Choi BK,Bobrowice P,et al.Use of combinatorialgenetic librarys to humanize N-linkd glycosylation in the yeastPichia pastoris.ProcNatl Acad Sci USA,2003,(4):5022.
  • 9Tsai H Y,Lin H Y,Fong Y C. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK,p38 and NF-kappaB pathway[J].European Journal of Pharmacology,2008.124-133.
  • 10Makihira S,Mine Y,Kosaka E. Titanium surface roughness accelerates RANKL-dependent differentiation in the osteoclast precursor cell line,RAW264.7[J].Dental Materials Journal,2007.739-745.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部